We read with great interest the report by Reig et al. describing unexpected early tumor recurrence in patients with hepatitis C virus-related
hepatocellular carcinoma (HCC) undergoing treatment with interferon (IFN)-free direct-acting
antivirals (DAA).
[1]
There is some debate as to whether DAA therapy increases the risk of liver cancer.
We report herein a clinicopathological case series of patients who experienced HCC
occurrence after DAA therapy, in order to shed some light on this emerging issue.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of HepatologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution.J Hepatol. 2016; 4: 8
- Report of the 19th follow-up survey of primary liver cancer in Japan.Hepatol Res. 2016; 46: 372-390
- Pathology of early hepatocellular carcinoma: progression from early to advanced.Semin Surg Oncol. 1996; 12: 197-203
- Serological and histological indices of hepatocellular carcinoma and tumor volume doubling time.Mol Clin Oncol. 2013; 6: 977-981
- Preoperative tumor marker doubling time is a useful predictor of recurrence and prognosis after hepatic resection of hepatocellular carcinoma.J Surg Oncol. 2010; 102: 490-496
- Tumor marker doubling time can be useful as a prognostic marker for hepatocellular carcinoma.Kanzo. 2014; 55: 550-552
- DAAs rapidly reduce inflammation but increase serum VEGF level: a rationale for tumor risk during anti-HCV treatment.PLoS One. 2016; 11
- On-treatment decrease of NKG2D correlates to early emergence of clinically evident hepatocellular carcinoma after interferon-free therapy for chronic hepatitis C.PLoS One. 2017; 12
Article info
Publication history
Published online: November 13, 2017
Identification
Copyright
© 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
